@LastManStand85 profile picture
Rheuma Doc @LastManStand85

🩺UK based Rheumatologist & Internal Medicine | Education | Arsenal Fan 35 Years -🏆🔴⚪️ | Just living the Dream ☔️| طب الروماتيزم | 🎬 🏋️‍♂️♟️🎱

Joined July 2023
  • Tweets 2,203
  • Following 476
  • Followers 4,436
1,006 Photos and videos
Pinned Tweet
Rheuma Doc@LastManStand85
7 Jan 2024
Steroids 2 mechanisms of action 1/ Genomic (activates @ 7.5mg-30mg Pred/day). Ceiling of saturation > 50mg. Limited additional anti-Inflammatory benefit beyond & ⬆️ Adverse 2/ NonGenomic. Act @ 100mg, Max sat 250-500mg & Less S/E as Shorter ⌛️ Less Is More! Great Slide 👇
4
99
243
47,918
Rheuma Doc retweeted
Mithu Maheswaranathan, MD@MithuRheum
Jun 15
🆕 Phase 3 RCT of #Brepocitinib (TYK2-JAK1 inhibitor) vs PBO in #Dermatomyositis (The VALOR Trial) 🔥 ⌛ Rapid onset: improvements as early as wk 4 💪 All pts had both active muscle skin disease 📈 Improvement in myositis activity, GC tapering #Myositis #Rheumatology #DermX
1
3
8
765
Why do some dreams have such a profound vivid emotional effect on you for weeks akin to reality? Its truly mind-boggling! any sleep study experts out there? 🛌 🧠..
234
bDMARDs & their impact on the immune system and their vaccination strategies.. 💉 #Rheumatology #MedTwitter
36
84
3,904
What ever happened to the prime samba free flowing Brazilian football team? the decline in quality over the years has been astonishing…
259
RT @RitasmanB: 👉Visco supplementation is not for all types of OA 🙏strongly recommended against grade 4 OA, acute OA, and large effusion OA…
20
folliculitis?
Curiosity
@CuriosityonX
Jun 7
First city ever built on mars. You get to name it. What's it gonna be?
446
Phase 3 INDIGO trial- IgG4 & Obexelimab - CD19 inhibits B cell function [rather than deplete] with more preservation of immune function. A significant 55% reduction in flares at 52W vs PBO, no major safety signals. Looking good…
NEJM
@NEJM
Jun 3
Original Article: Obexelimab for the Treatment of IgG4-Related Disease (phase 3 INDIGO trial results) nej.md/4fKYQG4 Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease nej.md/4fLybcd #EULAR2026 | @eular_org
Graph showing estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. The y-axis represents the probability of no flare, ranging from 0 to 1, and the x-axis shows time in months. The blue line indicates obexelimab while gray line indicates placebo. Notable statistics detail patients at risk, number of patients with flares, and median times. The hazard ratio is 0.44 with a p-value of <0.001.

ALT Graph showing estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. The y-axis represents the probability of no flare, ranging from 0 to 1, and the x-axis shows time in months. The blue line indicates obexelimab while gray line indicates placebo. Notable statistics detail patients at risk, number of patients with flares, and median times. The hazard ratio is 0.44 with a p-value of <0.001.

The image displays two line graphs. The top graph shows CD20 B-cell counts over time in weeks, comparing placebo and obexelimab treatments. The bottom graph presents serum IgG4 levels. Both graphs include patient numbers at different stages.

ALT The image displays two line graphs. The top graph shows CD20 B-cell counts over time in weeks, comparing placebo and obexelimab treatments. The bottom graph presents serum IgG4 levels. Both graphs include patient numbers at different stages.
5
22
2,083
EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome [2025] ✅ Definite total score >5.5 atleast 1 clinical domain anti-ARS ab mandatory ❓Probable >5 atleast 1 clinical domian, anti-ARS ab not mandatory #Rheumatology #MedTwitter
2
77
136
4,322
Rheuma Doc retweeted
May Kazem, MD MHA FRCPC (She/her)@MayKazem
Jun 4
#EULAR2026 #EULAR26 Factors associated with disease progression in #SystemicSclerosis Single and multi variable analyses
4
7
637
The Management of Fatigue in Rheumatic diseases #Rheumatology #MedTwitter
15
46
1,416
Anifrolumab & #Sjogrens small RCT 👇
TheDaoIndex@KDAO2011
Jun 3
#Anifrolumab for #Sjogren. Small RCT study noted improved CRESS, cSTAR, ESSPRI, ESSDAI. No issues with safety, no change in histology score, but MxA expression reduced in ANI group #EULAR26 #Plenary @RheumNow
12
34
1,984
The main causes of a raised CK 👇 [its not always myositis] #Rheumatology #MedTwiiter
Javi del Cid@javidlcid
Jun 3
Considering non-myopathic causes of elevated CK before initiating an extensive neuromuscular workup is essential for diagnostic efficiency, patient safety. Up to 1.3% of the general population exhibits asymptomatic or oligosymptomatic hyperCKemia, #eular2026 #london #autoimmune
16
35
2,639
Rheuma Doc retweeted
Md Yuzaiful Md Yusof@Yuz6Yusof
Jun 3
#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow #EULARBest
1
14
15
950
Rheuma Doc retweeted
Md Yuzaiful Md Yusof@Yuz6Yusof
Jun 3
#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow
8
11
658
Rheuma Doc retweeted
Janet Pope@Janetbirdope
Jun 3
You CAN identify #ILD in #rheumatic #diseases 🔜early With a brief #questionnaire Ask re ➡️dry cough ➡️dyspnea ➡️smoking Not sensitive but high #specificity Is it too late? Maybe chest #auscultation at the #bases would be better? 🤷 #EULAR2026 ABST#POS0433 @RheumNow
5
19
1,461
Sad but true…
The BMJ
@bmj_latest
Jun 3
Consultants in England are “quiet quitting” or looking to escape to Canada and Australia because they feel undervalued and disrespected, senior NHS doctors warn bmj.com/content/393/bmj-2026… youtube.com/watch?v=_OGSli92…
311
Rheuma Doc retweeted
Antoni Chan MD (Prof)
@synovialjoints
Jun 3
At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics
3
7
678
Rheuma Doc retweeted
NEJM
@NEJM
Jun 2
Presented at #EULAR2026: In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: nej.md/4fKYQG4 Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease nej.md/4fLybcd @eular_org
A line graph from an article titled "Obexelimab for the Treatment of IgG4-Related Disease," which shows estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. Below the graph is a footnote detail and the logo for the New England Journal of Medicine.

ALT A line graph from an article titled "Obexelimab for the Treatment of IgG4-Related Disease," which shows estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. Below the graph is a footnote detail and the logo for the New England Journal of Medicine.

1
73
234
24,154
Neurobehcets 👇 #Rheumatology #MedTwitter
Rheumatology update
@aabdogafar
Jun 1
Neuro-Behçet
9
20
1,636
Pain.
206
Load more